Quantcast

Latest Clinical trial Stories

2014-07-15 12:28:31

Two drugs to be studied in North America and Europe in volunteers at high risk for disease COPENHAGEN, Denmark, July 15, 2014 /PRNewswire/ -- Researchers from the Banner Alzheimer's Institute (BAI) today announced a partnership with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs--an active immunotherapy and an oral medication--can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for...

2014-07-15 04:22:22

ABERDEEN, Scotland and SINGAPORE, July 15, 2014 /PRNewswire/ -- TauRx Therapeutics Ltd [http://www.taurx.com ] today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX(TM) [http://taurx.com/lmtx-for-ad ], a tau aggregation inhibitor, for the treatment of Alzheimer's Disease [AD]. This placebo-controlled clinical trial (Protocol TRx-237-015 [http://taurx.com/015-clinical-study.html ]) has...

2014-07-14 23:04:05

Key Questions & Memorable Quotes from #eCongress Toronto, Canada (PRWEB) July 14, 2014 Throughout this past June 100s of mid-to-senior level executives from across the clinical trials space, representing 38 countries globally, registered for Xtalks 1st Annual eCongress webinar series entitled “Optimizing Patient Participation in Clinical Trials. Attract. Engage. Retain.” This well-attended eCongress kicked off with internationally renowned R&D expert, Ken Getz, of Tufts CSDD,...

2014-07-11 08:24:57

SYDNEY and BEDMINSTER, N.J., July 11, 2014 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) today provided feedback on its 9 July End-of-Review (EOR) meeting with the United States Food and Drug Administration (FDA). The meeting was held to discuss the feasibility and requirements for approving Moxduo, an immediate release Dual Opioid(®), for the treatment of moderate to severe acute pain. In advance of the meeting, QRxPharma outlined several questions to discuss with...

2014-07-10 10:28:40

Boston Children's Hospital Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS ONE. The study highlights...

2014-07-09 23:06:47

Patented Smart Pill Bottle Company Will Use Capital to Scale the Product and Service New York, NY (PRWEB) July 09, 2014 AdhereTech (AdhereTech.com), a healthcare technology company that makes patented smart pill bottles to improve medication adherence and patient engagement, today announced its initial closing of $1.75 million in Series A financing. The round was led by undisclosed investors with a focus in healthcare. AdhereTech will use the investment to scale its service and meet the...

2014-07-09 16:28:10

Study calls for more focus on long-term outcomes in pediatric trials of drugs intended for chronic use BOSTON, July 9, 2014 /PRNewswire-USNewswire/ -- Over the last 60 years, the U.S. Food and Drug Administration (FDA) approved 20 medications for attention deficit/hyperactivity disorder (ADHD) based on clinical trials that were not designed to study their long-term efficacy and safety or to detect rare adverse events, researchers at Boston Children's Hospital report today in PLOS...

2014-07-07 16:24:20

- MPS IV A patients and families urge swift, publicly funded access to life-altering drug VIMIZIM(TM) - VANCOUVER, July 7, 2014 /CNW/ - The Canadian Society for Mucopolysaccharide & Related Diseases Inc. (Canadian MPS Society) is thrilled by Health Canada's recent approval of VIMIZIM(TM) (elosulfase alfa), the first and only pharmaceutical treatment option available for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Mucopolysaccharidosis IVA (MPS...

2014-07-07 04:20:56

- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO(TM) for the management of moderate to severe acute pain in adult patients in a medically supervised environment. ZALVISO(TM) is a drug-device...

2014-07-05 23:00:05

ResearchMoz.us includes new market research report, "Paralysis Global Clinical Trials Review, H1, 2014," to its huge collection of research reports. Albany,New York (PRWEB) July 06, 2014 "Paralysis Global Clinical Trials Review, H1, 2014" provides data on the paralysis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on paralysis. It includes an overview of the trial numbers and their recruitment status as per...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related